Julius Muller

Julius Muller

Auto-generated profile, based on publicly available information

Julius Muller

Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2012 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
VMValentina Migliori
Valentina Migliori
JMJulius Müller
Julius Müller
SPSameer Phalke
Sameer Phalke
DLDiana Low
Diana Low
MBMarco Bezzi
Marco Bezzi
EGErnesto Guccione
Ernesto Guccione

1 September 2013 in Genes & Development
Verified
Journal Article
Open access
PDF file
MBMarco Bezzi
Marco Bezzi
STShun Xie Teo
Shun Xie Teo
JMJulius Muller
Julius Muller
WMWei Chuen Mok
Wei Chuen Mok
SSSanjeeb Kumar Sahu
Sanjeeb Kumar Sahu
Ernesto GuccioneErnesto Guccione
Ernesto Guccione
The tight control of gene expression at the level of both transcription and post-transcriptional RNA processing is essential for mammalian development. We here investigate the role of protein arginine methyltransferase 5 (PRMT5), a putative splicing regulator and transcriptional cofactor, in mammalian development. We demonstrate that selective deletion of PRMT5 in neural stem/progenitor cells (NPCs) leads to postnatal death in mice. At the molecular level, the absence of PRMT5 results in reduced methylation of Sm proteins, aberrant constitutive splicing, and the alternative splicing of specific mRNAs with weak 5′ donor sites. Intriguingly, the products of these mRNAs are, among others, several proteins regulating cell cycle progression. We identify Mdm4 as one of these key mRNAs that senses the defects in the spliceosomal machinery and transduces the signal to activate the p53 response, providing a mechanistic explanation of the phenotype observed in vivo. Our data demonstrate that PRMT5 is a master regulator of splicing in mammals and uncover a new role for the Mdm4 pre-mRNA, which could be exploited for anti-cancer therapy.

1 November 2013 in Cell Reports
Verified
Journal Article
Open access
ABAdam Burton
Adam Burton
JMJulius Muller
Julius Muller
STShengjiang Tu
Shengjiang Tu
PPPablo Padilla-Longoria
Pablo Padilla-Longoria
Ernesto GuccioneErnesto Guccione
Ernesto Guccione
MTMaria-Elena Torres-Padilla
Maria-Elena Torres-Padilla
Cell plasticity or potency is necessary for the formation of multiple cell types. The mechanisms underlying this plasticity are largely unknown. Preimplantation mouse embryos undergo drastic changes in cellular potency, starting with the totipotent zygote through to the formation of the pluripotent inner cell mass (ICM) and differentiated trophectoderm in the blastocyst. Here, we set out to identify and functionally characterize chromatin modifiers that define the transitions of potency and cell fate in the mouse embryo. Using a quantitative microfluidics approach in single cells, we show that developmental transitions are marked by distinctive combinatorial profiles of epigenetic modifiers. Pluripotent cells of the ICM are distinct from their differentiated trophectoderm counterparts. We show that PRDM14 is heterogeneously expressed in 4-cell-stage embryos. Forced expression of PRDM14 at the 2-cell stage leads to increased H3R26me2 and can induce a pluripotent ICM fate. Our results shed light on the epigenetic networks that govern cellular potency and identity in vivo.

7 September 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMian Bi
Mian Bi
AGAmadeus Gladbach
Amadeus Gladbach
JEJanet van Eersel
Janet van Eersel
AIArne Ittner
Arne Ittner
MPMagdalena Przybyla
Magdalena Przybyla
LILars Matthias Ittner
Lars Matthias Ittner
Neuronal excitotoxicity induced by aberrant excitation of glutamatergic receptors contributes to brain damage in stroke. Here we show that tau-deficient (tau−/−) mice are profoundly protected from excitotoxic brain damage and neurological deficits following experimental stroke, using a middle cerebral artery occlusion with reperfusion model. Mechanistically, we show that this protection is due to site-specific inhibition of glutamate-induced and Ras/ERK-mediated toxicity by accumulation of Ras-inhibiting SynGAP1, which resides in a post-synaptic complex with tau. Accordingly, reducing SynGAP1 levels in tau−/− mice abolished the protection from pharmacologically induced excitotoxicity and middle cerebral artery occlusion-induced brain damage. Conversely, over-expression of SynGAP1 prevented excitotoxic ERK activation in wild-type neurons. Our findings suggest that tau mediates excitotoxic Ras/ERK signaling by controlling post-synaptic compartmentalization of SynGAP1.

28 January 2016 in Nature Communications
Verified
Journal Article
Open access
SNSophie Nolivos
Sophie Nolivos
AUAmy L. Upton
Amy L. Upton
ABAnjana Badrinarayanan
Anjana Badrinarayanan
JMJulius Müller
Julius Müller
KZKatarzyna Zawadzka
Katarzyna Zawadzka
DSDavid Sherratt
David Sherratt
The Escherichia coli SMC complex, MukBEF, forms clusters of molecules that interact with the decatenase topisomerase IV and which are normally associated with the chromosome replication origin region (ori). Here we demonstrate an additional ATP-hydrolysis-dependent association of MukBEF with the replication termination region (ter). Consistent with this, MukBEF interacts with MatP, which binds matS sites in ter. MatP displaces wild-type MukBEF complexes from ter, thereby facilitating their association with ori, and limiting the availability of topoisomerase IV (TopoIV) at ter. Displacement of MukBEF is impaired when MukB ATP hydrolysis is compromised and when MatP is absent, leading to a stable association of ter and MukBEF. Impairing the TopoIV-MukBEF interaction delays sister ter segregation in cells lacking MatP. We propose that the interplay between MukBEF and MatP directs chromosome organization in relation to MukBEF clusters and associated topisomerase IV, thereby ensuring timely chromosome unlinking and segregation.

20 April 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CKCheryl M. Koh
Cheryl M. Koh
EKEkta Khattar
Ekta Khattar
SLShi Chi Leow
Shi Chi Leow
CLChia Yi Liu
Chia Yi Liu
JMJulius Muller
Julius Muller
Vinay TergaonkarVinay Tergaonkar
Vinay Tergaonkar
Constitutively active MYC and reactivated telomerase often coexist in cancers. While reactivation of telomerase is thought to be essential for replicative immortality, MYC, in conjunction with cofactors, confers several growth advantages to cancer cells. It is known that the reactivation of TERT, the catalytic subunit of telomerase, is limiting for reconstituting telomerase activity in tumors. However, while reactivation of TERT has been functionally linked to the acquisition of several “hallmarks of cancer” in tumors, the molecular mechanisms by which this occurs and whether these mechanisms are distinct from the role of telomerase on telomeres is not clear. Here, we demonstrated that first-generation TERT-null mice, unlike Terc-null mice, show delayed onset of MYC-induced lymphomagenesis. We further determined that TERT is a regulator of MYC stability in cancer. TERT stabilized MYC levels on chromatin, contributing to either activation or repression of its target genes. TERT regulated MYC ubiquitination and proteasomal degradation, and this effect of TERT was independent of its reverse transcriptase activity and role in telomere elongation. Based on these data, we conclude that reactivation of TERT, a direct transcriptional MYC target in tumors, provides a feed-forward mechanism to potentiate MYC-dependent oncogenesis.